Advances in treating T-cell lymphoma
Franco Cavalli, MD, FRCP, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, summarizes the latest developments in T-cell lymphoma management. Data from a Phase III trial (NCT02631239) comparing ESA (pegaspargase, etoposide and dexamethasone) with sandwiched radiotherapy to MESA (ESA plus methotrexate) in patients with natural killer/T-cell lymphoma was discussed, with ESA being more efficacious and less toxic. Standard allogenic transplantation was additionally found to be as effective as haploidentical transplantation, widening the indication for allogeneic transplantation. Alternative approaches to chemotherapy including the HDAC inhibitor romidepsin and PI3K inhibitor duvelisib were also discussed, potentially paving the way for new lines of treatment. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
-
Category
No comments found